↓ Skip to main content

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forUGT1A1and Atazanavir Prescribing

Overview of attention for article published in Clinical Pharmacology & Therapeutics, November 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

blogs
1 blog
twitter
2 tweeters

Citations

dimensions_citation
95 Dimensions

Readers on

mendeley
105 Mendeley
Title
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forUGT1A1and Atazanavir Prescribing
Published in
Clinical Pharmacology & Therapeutics, November 2015
DOI 10.1002/cpt.269
Pubmed ID
Authors

RS Gammal, MH Court, CE Haidar, OF Iwuchukwu, AH Gaur, M Alvarellos, C Guillemette, JL Lennox, M Whirl-Carrillo, SS Brummel, MJ Ratain, TE Klein, BR Schackman, KE Caudle, DW Haas

Abstract

The antiretroviral protease inhibitor atazanavir inhibits hepatic uridine diphosphate glucuronosyltransferase (UGT) 1A1, thereby preventing the glucuronidation and elimination of bilirubin. Resultant indirect hyperbilirubinemia with jaundice can cause premature discontinuation of atazanavir. Risk for bilirubin-related discontinuation is highest among individuals who carry two UGT1A1 decreased function alleles (UGT1A1*28 or *37). We summarize published literature that supports this association and provide recommendations for atazanavir prescribing when UGT1A1 genotype is known (updates at www.pharmgkb.org). This article is protected by copyright. All rights reserved.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 105 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 21 20%
Student > Master 14 13%
Student > Ph. D. Student 11 10%
Other 10 10%
Student > Bachelor 9 9%
Other 23 22%
Unknown 17 16%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 23 22%
Medicine and Dentistry 20 19%
Biochemistry, Genetics and Molecular Biology 18 17%
Agricultural and Biological Sciences 10 10%
Economics, Econometrics and Finance 2 2%
Other 9 9%
Unknown 23 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 October 2016.
All research outputs
#1,805,717
of 12,444,560 outputs
Outputs from Clinical Pharmacology & Therapeutics
#368
of 2,788 outputs
Outputs of similar age
#50,854
of 273,578 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#6
of 39 outputs
Altmetric has tracked 12,444,560 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,788 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,578 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.